» Articles » PMID: 38753845

Bone Mineral Density and Related Clinical and Laboratory Factors in Peritoneal Dialysis Patients: Implications for Bone Health Management

Overview
Journal PLoS One
Date 2024 May 16
PMID 38753845
Authors
Affiliations
Soon will be listed here.
Abstract

Background: End-stage renal disease (ESRD) patients often experience accelerated bone turnover, leading to osteoporosis and osteopenia. This study aimed to determine the prevalence of osteoporosis in Peritoneal Dialysis (PD) patients using bone mineral density (BMD) measurements obtained through dual-energy X-ray absorptiometry (DEXA) scan and to explore any possible associations with clinical and biochemical factors.

Methods: In this cross-sectional study, we enrolled 76 peritoneal dialysis patients from the dialysis center at An-Najah National University Hospital in Nablus, Palestine. We used the DEXA scan to measure BMD at the lumbar spine and hip, with values expressed as T-scores. We conducted a multivariate analysis to explore the relationship between BMD and clinical and biochemical parameters.

Results: Over half (52.6%) of the PD patients had osteoporosis, with a higher prevalence observed among patients with lower BMI (p<0.001). Higher alkaline phosphatase levels were found among osteoporotic patients compared to non-osteoporotic patients (p = 0.045). Vitamin D deficiency was also prevalent in this population, affecting 86.6% of patients. No significant correlation was found between 25 vitamin D levels and BMD. No significant correlation was found between Parathyroid hormone (PTH) levels and BMD.

Conclusion: A notable proportion of PD patients experience reduced BMD. Our study found no correlation between vitamin D levels and BMD, but it highlighted the significant vitamin D deficiency in this population. Furthermore, our analysis indicated a positive correlation between BMI and BMD, especially in the femoral neck area. This underscores the significance of addressing bone health in PD patients to mitigate the risk of fractures and improve their overall well-being.

Citing Articles

Brown Tumors: The Hidden Face of Primary and Renal Hyperparathyroidism Amid Real-Life Settings.

Carsote M, Ciobica M, Sima O, Valea A, Bondor C, Geleriu A J Clin Med. 2024; 13(13).

PMID: 38999413 PMC: 11242279. DOI: 10.3390/jcm13133847.

References
1.
Kerschbaum J, Vychytil A, Lhotta K, Prischl F, Wiesholzer M, Machhold-Fabrizii V . Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. PLoS One. 2013; 8(7):e67836. PMC: 3699473. DOI: 10.1371/journal.pone.0067836. View

2.
Pongchaiyakul C, Pongskul C, Ruengjui S, Sirivongs D . Bone mineral density among patients undergoing continuous ambulatory peritoneal dialysis (CAPD). J Med Assoc Thai. 2006; 88 Suppl 5:S40-5. View

3.
Negri A, Barone R, Quiroga M, Bravo M, Marino A, Fradinger E . Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int. 2004; 24(2):163-8. View

4.
Nazzal Z, Khader S, Zawyani H, Abdallah M, Sawalmeh O, Hamdan Z . Bone mineral density in Palestinian patients with end-stage renal disease and the related clinical and biochemical factors: Cross-sectional study. PLoS One. 2020; 15(11):e0241201. PMC: 7661051. DOI: 10.1371/journal.pone.0241201. View

5.
Fonseca H, Moreira-Goncalves D, Appell Coriolano H, Duarte J . Bone quality: the determinants of bone strength and fragility. Sports Med. 2013; 44(1):37-53. DOI: 10.1007/s40279-013-0100-7. View